Landmark independent publication in nature medicine validates caredx alloview ai-enabled risk prediction model and demonstrates allosure kidney detects subclinical rejection in stable patients

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 american transplant congress, the publication in nature medicine1 of findings from the largest, real-world study of its kind, assessing the role of allosure® donor-derived cell-free dna (dd-cfdna) and.
CDNA Ratings Summary
CDNA Quant Ranking